Baseline characteristics and 1-year follow-up of chinese atrial fibrillation patients according to age: A registry study

PACE - Pacing and Clinical Electrophysiology

Volumn 37, Issue 10, 2014, Pages 1392-1403

  Chen, Tao ^a   Yang, Yan Min ^a   Tan, Hui Qiong ^a   Liang, Yan ^a   Zhu, Jun ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

atrial fibrillation; Chinese; evidence based medicine; prognosis; registry

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIGOXIN; PROPAFENONE; SOTALOL; WARFARIN;

AGED; ARTICLE; CARDIAC PATIENT; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CHINESE; COMPARATIVE STUDY; EMBOLISM; FEMALE; FOLLOW UP; GROUPS BY AGE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTPATIENT DEPARTMENT; PROGNOSIS; PROSPECTIVE STUDY; SYSTEMIC EMBOLISM; VALVULAR HEART DISEASE; AGE; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; COMPLICATION; MIDDLE AGED; REGISTER; TIME;

AGE FACTORS; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; REGISTRIES; TIME FACTORS;

EID: 84908021981     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/pace.12443     Document Type: Article

References (19)

1. Zhou Z, Hu D,. An epidemiological study on the prevalence of atrial fibrillation in the Chinese population of mainland China. J Epidemiol 2008; 18: 209-216.
2. Hu D, Sun Y,. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. J Am Coll Cardiol 2008; 52: 865-868.
3. Hu D, Sun Y, Zhou Z,. Risk factors for stroke in Chinese with non valvular atrial fibrillation: A case-control study. Chin J Intern Med 2003; 42: 157-161.
4. Zhou Z, Hu D, Chen J,. An epidemiological survey of atrial fibrillation in China. Chin J Intern Med 2004; 43: 491-494.
5. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ,. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272.
6. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
7. Olshansky B, Rosenfeld LE, Warner AL, Solomon AJ, O'Neill G, Sharma A, et al. The atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study: Approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004; 43: 1201-1208.
8. Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal B, et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol 2011; 57: 313-321.
9. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation 2003; 107: 2920-2925.
10. Hart RG, Pearce LA, Aguilar MI,. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
11. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomized controlled trial. Lancet 2007; 370: 493-503.
12. Rash A, Downes T, Portner R, Yeo WW, Morgan N, Channer KS,. A randomized controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing 2007; 36: 151-156.
13. Hu D, Zhang H, Sun Y,. The randomized study of efficiency and safety of antithrombotic therapy in non-valvular atrial fibrillation: Warfarin compared with aspirin. Chin J Cardiol 2006; 34: 295-298.
14. ACTIVE Writing Group of the ACTIVE Investigators., Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of vascular events (ACTIVE W): A randomized controlled trial. Lancet 2006; 367: 1903-1912.
15. Poli D, Antonucci E, Testa S, Tosetto A, Ageno W, Palareti G,. Bleeding risk in very old patients on vitamin K antagonist treatment: Results of a prospective collaborative study on elderly patients followed by Italian Centers for Anticoagulation. Circulation 2011; 124: 824-829.
16. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998; 98: 946-952.
17. Stewart S, Hart CL, Hole DJ, McMurray JJ,. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113: 359-364.
18. Nieuwlaat R, Prins MH, Le Heuzey JY, Vardas PE, Aliot E, Santini M, et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: Follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J 2008; 29: 1181-1189.
19. Wolf PA, Abbott RD, Kannel WB,. Atrial fibrillation as an independent risk factor for stroke: The Framingham study. Stroke 1991; 22: 983-988.